The clinical application of synthetic tumor peptide‐based vaccines is currently limited to
patients with specified major histocompatibility complex (MHC) class I alleles. Such logistic …

Several studies have shown that vaccine therapy using dendritic cells (DCs) pulsed with
specific tumor antigen peptides can effectively induce antitumor immunity. Peptide-pulsed …

The context in which an antigen is presented shapes the nature of the immune response to
that antigen and can result in B cell activation, T cell activation, or immune tolerance. To …

Dendritic cells (DCs) constitute a specialised system of antigen-presenting cells with a high
capacity to induce and to modulate the immune response against microbial, tumour and self …

Recent insights in antigen presentation, the identification of human tumor antigens, and the
demonstration of MHC class-I-restricted cytotoxic T lymphocyte (CTL) recognition of peptides …

Previously we have demonstrated that two doses of a cytotoxic T lymphocyte (CTL) epitope–
based peptide vaccine of human papillomavirus type 16 (HPV 16) E7 aa 49–57 elicit …

The unique antigen-presenting capabilities of dendritic cells (DCs) make them an attractive
means with which to initiate an antitumor immune response. Using DCs transduced with …

Dendritic cells (dc) are potent antigen-presenting cells that play a critical role in the initiation
of cellular immune responses. Using a BALB/c syngeneic colon carcinoma cell line …

Background The development of effective cancer vaccines still remains a challenge. Despite
the crucial role of plasmacytoid dendritic cells (pDCs) in anti-tumor responses, their …

Dendritic cells (DCs) are professional Ag-presenting cells that are being considered as
potential immunotherapeutic agents to promote host immune responses against tumor Ags …